{"entity":{"id":"tst001","kind":"drug","name":"TST001","aka":[],"tldr":"TST001 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.","summary":"TST001 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by Transcenta Therapeutics (Hangzhou) Co., Ltd., in metastatic cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of TST001","url":"https://clinicaltrials.gov/search?intr=TST001"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04396821","nct04495296"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"TST001","modality":"Monoclonal antibody","mechanism":"A monoclonal antibody, as described in the registry record.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tst001/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"trial":[{"id":"nct04396821","kind":"trial","name":"A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04396821/"},{"id":"nct04495296","kind":"trial","name":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04495296/"}]}}